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  The link between PI3K and cancer is among 
the strongest in the genome. PI3K sits in a critical node 
in cancer signaling space where it integrates growth and 
survival signals from RTKs and Ras to the mTOR, MAPK, 
FOXO1 and GSK3β signaling pathways. The Class I 
PI3Ks are dimeric kinases comprised of one regulatory 
subunit (p85 α, β, or γ) and one catalytic subunit (p110 α, 
β, or γ) which phosphorylate phosphoinositides at the D-3 
position of the inositol ring in response to environmental 
cues.  Constitutive activation of the PI3Ks is transforming 
in experimental models and in human breast, colon and 
endometrial cancer, activating mutations in the gene for 
PIK3CA (p110α) are seen in 30% of the patient population. 
Inactivating mutations to the p85 regulatory subunit have 
been described in a subpopulation (~10%) of colorectal 
cancer patients.  Moreover, the PTEN phosphoinositide 
phosphatase, nature’s brake to proliferative PI3K 
signaling, is a frequently mutated tumor suppressor gene 
[1, 2 and references therein].
Given the successes over the last decade in 
developing small molecule inhibitors targeting the 
BCR-ABL, EGFR, and BRAF oncogenic kinases, it is 
not surprising that numerous PI3K inhibitors have been 
developed and are currently being evaluated in human 
clinical  trials.  Despite  the  fact  that  among  the  p110 
isoforms, p110α is preferentially mutated in cancer, the 
first wave of PI3K inhibitors to enter the clinic consisted 
of non-isoform selective (pan) molecules.  While these 
inhibitors are broadly active in preclinical cancer models 
[3, 4] concern as to whether the lack of selectivity may 
adversely impact the therapeutic index has led to follow 
up efforts to develop isoform-selective PI3K inhibitors. 
Working from an imidazopyridine-based scaffold, 
Schmidt-Kittler et al optimized PI3Kα-selective inhibitors 
with nM potency against PI3Kα  (J-series). Among class 
I  PI3Ks  (α,  β,  γ,  δ)  the  J-series  compounds  averaged 
20 to 30 fold selectivity in favor of the p110α isoform 
in vitro but did not discriminate between wt and mutant 
(E545K, H1047R) forms of the enzyme. Representative 
compounds from the series inhibited growth and phospho-
AKT levels in HCT116 cells in the 100 nM range in vitro, 
independent of PI3K mutational status.  An unexpected 
finding  occurred  during  the  in  vivo  evaluation  of  two 
such compounds from the series. Although phospho-AKT 
levels were robustly inhibited in HCT116 xenograft tumor 
tissue, this translated into only modest effects on tumor 
growth inhibition. In contrast, when the compounds were 
evaluated in a metastatic version of the HCT116 model, 
wherein tumor cells injected into the spleen spread to 
the liver and lungs, the emergence of distant metastases 
was  significantly  curtailed  [5].  The  conclusions  from 
this work – that PI3Kα inhibitors may be more useful for 
limiting the spread of a primary tumor to distant sites than 
treating established tumors – would be strengthened by 
additional studies incorporating isoform specific shRNAs 
in one or more in vivo tumor models. Still, the findings 
are provocative and raise many interesting questions.
Why does in vitro anti-proliferative activity not 
translate to the in vivo setting? 
J124  and  J128  displayed  potent  inhibition  of 
HCT116 growth in vitro in the nM range. Arcaro and 
coworkers also reported single agent activity in vitro with 
PI3Kα-selective inhibitors in a panel of medulloblastoma 
cell lines [6].
Assuming  intra-tumoral  levels  of  the  J-series 
compounds reached exposures equivalent to those 
assessed  in  vitro  (~100nM),  why  was  potent  anti-
proliferative activity against the primary tumor not 
observed despite effective modulation of the phospho-
AKT pharmacodynamic marker?  The data suggest that 
modulation of phospho-AKT is insufficient for in vivo 
anti-tumor activity and beg the question – what PI3Kα-
dependent processes impact the spread of the primary 
tumor? One also can’t help but wonder whether p110α 
mutational status impacts the metastatic potential of a 
tumor.Oncotarget 2 www.impactjournals.com/oncotarget
What is the mechanism of action through which 
PI3Kα regulates metastasis?
PI3Ks can phosphorylate both lipid and protein 
substrates. It is tempting to speculate that the modulation 
of as yet undefined substrates regulating angiogenesis, cell 
adhesion or migration accounts for these observations. 
Identification  of  these  biomarkers  will  be  essential  for 
successful clinical evaluation of these compounds. 
How should α-selective inhibitors be evaluated in 
the clinic?
If indeed the utility of such compounds lies in 
preventing cancer spread, the best setting for single agent 
treatment may be in situations where measurable disease 
is  not  an  issue  (i.e.  surgically  removed  or  irradiated) 
and prevention of new lesions is needed.  While first or 
second line treatment of advanced or metastatic disease 
may benefit patients by virtue of preventing new lesions, 
the ideal treatment setting is likely as an adjuvant therapy 
in patients with initially resectable localized disease with 
high metastatic recurrence rates. A potential endpoint 
would be progression free survival following surgery in 
patients receiving PI3Kα inhibitor therapy vs. standard of 
care adjuvant chemotherapy.
PI3Kα  inhibitor  therapy  may  also  be  well  suited 
for use in combination with other targeted or cytotoxic 
agents, as has been shown for pan PI3K inhibitors and 
MEK inhibitors in models of basal-like breast cancer [7].
In  closing,  the  findings  of  Schmidt-Kittler  et  al 
leave fertile ground for exploratory research in numerous 
directions.  The  emergence  of  PI3Kα-selective  tool 
compounds  should  catalyze  future  discoveries  that  can 
inform the medical community on the optimal use of such 
agents upon their arrival in the clinic.
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